ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis

NASDAQ:ACAD • US0042251084

24.97 USD
+0.38 (+1.55%)
At close: Feb 25, 2026
25.28 USD
+0.31 (+1.24%)
After Hours: 2/25/2026, 7:50:59 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

ACAD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make ACAD a good candidate for value investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • ACAD had positive earnings in the past year.
  • ACAD had a positive operating cash flow in the past year.
  • ACAD had negative earnings in each of the past 5 years.
  • ACAD had a negative operating cash flow in each of the past 5 years.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • ACAD's Return On Assets of 19.63% is amongst the best of the industry. ACAD outperforms 97.12% of its industry peers.
  • Looking at the Return On Equity, with a value of 28.47%, ACAD belongs to the top of the industry, outperforming 97.12% of the companies in the same industry.
  • ACAD has a Return On Invested Capital of 7.66%. This is amongst the best in the industry. ACAD outperforms 93.47% of its industry peers.
Industry RankSector Rank
ROA 19.63%
ROE 28.47%
ROIC 7.66%
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • ACAD has a Profit Margin of 24.94%. This is amongst the best in the industry. ACAD outperforms 95.01% of its industry peers.
  • With an excellent Operating Margin value of 9.02%, ACAD belongs to the best of the industry, outperforming 90.98% of the companies in the same industry.
  • ACAD's Gross Margin of 91.92% is amongst the best of the industry. ACAD outperforms 93.67% of its industry peers.
  • In the last couple of years the Gross Margin of ACAD has grown nicely.
Industry RankSector Rank
OM 9.02%
PM (TTM) 24.94%
GM 91.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
  • The number of shares outstanding for ACAD has been increased compared to 1 year ago.
  • ACAD has more shares outstanding than it did 5 years ago.
  • ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • ACAD has an Altman-Z score of 5.51. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
  • ACAD's Altman-Z score of 5.51 is fine compared to the rest of the industry. ACAD outperforms 73.13% of its industry peers.
  • There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.51
ROIC/WACC0.88
WACC8.68%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.02 indicates that ACAD has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.02, ACAD is doing worse than 64.30% of the companies in the same industry.
  • A Quick Ratio of 2.94 indicates that ACAD has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.94, ACAD is not doing good in the industry: 62.76% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.94
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ACAD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.10%.
  • The Revenue has grown by 121.75% in the past year. This is a very strong growth!
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%

3.2 Future

  • ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.44% yearly.
  • ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.58% yearly.
EPS Next Y70.03%
EPS Next 2Y26.24%
EPS Next 3Y33.41%
EPS Next 5Y38.44%
Revenue Next Year11.07%
Revenue Next 2Y11.15%
Revenue Next 3Y10.89%
Revenue Next 5Y10.58%

3.3 Evolution

ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 500M 1B 1.5B 2B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 37.27, ACAD can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, ACAD is valued cheaper than 91.94% of the companies in the same industry.
  • ACAD's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.05.
  • A Price/Forward Earnings ratio of 32.64 indicates a quite expensive valuation of ACAD.
  • Based on the Price/Forward Earnings ratio, ACAD is valued cheaply inside the industry as 91.55% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.03. ACAD is around the same levels.
Industry RankSector Rank
PE 37.27
Fwd PE 32.64
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • ACAD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ACAD is cheaper than 93.47% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 95.97% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 19.4
EV/EBITDA 25.12
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • ACAD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of ACAD may justify a higher PE ratio.
  • ACAD's earnings are expected to grow with 33.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.53
PEG (5Y)N/A
EPS Next 2Y26.24%
EPS Next 3Y33.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ACAD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (2/25/2026, 7:50:59 PM)

After market: 25.28 +0.31 (+1.24%)

24.97

+0.38 (+1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-25
Inst Owners101.21%
Inst Owner Change-2.49%
Ins Owners0.26%
Ins Owner Change-1.09%
Market Cap4.22B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts76.92
Price Target31.73 (27.07%)
Short Float %5.56%
Short Ratio6.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)2.78%
PT rev (3m)7.88%
EPS NQ rev (1m)-2.32%
EPS NQ rev (3m)-14.84%
EPS NY rev (1m)-1.3%
EPS NY rev (3m)39.89%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)-0.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.91%
Valuation
Industry RankSector Rank
PE 37.27
Fwd PE 32.64
P/S 4.03
P/FCF 19.4
P/OCF 13.3
P/B 4.61
P/tB 5.24
EV/EBITDA 25.12
EPS(TTM)0.67
EY2.68%
EPS(NY)0.77
Fwd EY3.06%
FCF(TTM)1.29
FCFY5.15%
OCF(TTM)1.88
OCFY7.52%
SpS6.19
BVpS5.42
TBVpS4.76
PEG (NY)0.53
PEG (5Y)N/A
Graham Number9.04
Profitability
Industry RankSector Rank
ROA 19.63%
ROE 28.47%
ROCE 9.69%
ROIC 7.66%
ROICexc 58.65%
ROICexgc 479.54%
OM 9.02%
PM (TTM) 24.94%
GM 91.92%
FCFM 20.79%
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 711.57%
Cap/Sales 9.55%
Interest Coverage 250
Cash Conversion 292.92%
Profit Quality 83.36%
Current Ratio 3.02
Quick Ratio 2.94
Altman-Z 5.51
F-Score4
WACC8.68%
ROIC/WACC0.88
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y70.03%
EPS Next 2Y26.24%
EPS Next 3Y33.41%
EPS Next 5Y38.44%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year11.07%
Revenue Next 2Y11.15%
Revenue Next 3Y10.89%
Revenue Next 5Y10.58%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.83%
EBIT Next 3Y26.42%
EBIT Next 5Y33.87%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A

ACADIA PHARMACEUTICALS INC / ACAD FAQ

What is the fundamental rating for ACAD stock?

ChartMill assigns a fundamental rating of 6 / 10 to ACAD.


What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?

ChartMill assigns a valuation rating of 7 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Undervalued.


Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?

ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of ACADIA PHARMACEUTICALS INC (ACAD) stock?

The Price/Earnings (PE) ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 37.27 and the Price/Book (PB) ratio is 4.61.


Can you provide the financial health for ACAD stock?

The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 7 / 10.